Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramosetron ODT for Postdischarge Nausea and Vomiting
NCT04297293Phase 4Unknown
- Sponsor
- Seoul National University Hospital
- Start
- May 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ramosetron in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Seoul National University Hospital. Primary endpoints: The change in the occurrence of postoperative nausea at 48 hour and The change in the occurrence of postoperative vomiting at 48 hour. Status: unknown.
02
Drugs
ramosetron
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT04297293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04297293.